Relay & Fio Announce Execution of Definitive Agreement for Malaria Deployment
September 21 2021 - 04:05PM
Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA,
OTC: RYMDF, Frankfurt: EIY2) and Fio Corporation
(“Fio”) – together through their joint venture, Fionet Rapid
Response Group (“FRR”) – are pleased to report on the signing of a
definitive agreement and provide an update on the deployment to
combat the malaria epidemic in Rwanda, East Africa.
The Rwanda Ministry of Health signed a
procurement agreement with FRR to deploy the Fionet Platform for
decentralized malaria testing. Under the terms of the agreement,
FRR will receive CAD $750,000, which has been already secured by
the Ministry, to deploy the Fionet Platform for six months for use
by 180 community-based healthcare workers. The six-month deployment
is a pilot to evaluate a national scale up, which could then lead
to a subsequent agreement to deploy Fionet for Rwanda’s 60,000
healthcare workers.
“Rwanda is a fast-growing African leader in
using innovative Information and Communications Technology (ICT) to
bring rapid, high-quality, connected diagnostics to the community
level everywhere. We are confident the Fionet Platform will serve
Rwanda’s objective very well. COVID-19 continues to demonstrate
that such an objective is just as important in developed
countries,” said Dr. Michael Greenberg, CEO of FRR.
Malaria is a serious, sometimes fatal, disease
spread by mosquitoes and caused by a parasite. It is contracted by
over 200 million people per year, and kills over 400,000 people
annually, of whom two-thirds are children under the age of five1.
Nearly half of the world’s population lives in areas at risk of
malaria transmission.
Rwanda has a population of 12.6 million and is
the one of the most densely populated country in Africa2. It is in
the top 25 countries in the world with the highest number of
malaria cases and deaths and takes fighting the disease very
seriously3.
The Fionet Platform can enhance the quality of
healthcare delivered in decentralized health centers, health posts,
and communities in Rwanda. Frontline health care professionals will
use Fionet Mobile Devices to support frontline testing through the
continuous capture and transmission of comprehensive medical data
to a centralized aggregation point. In real time, Fionet Portals
allow off-site supervisors and managers to track and direct
frontline action based on accurate epidemiological information.
Fionet’s accuracy, data capture and distribution
capability was demonstrated in a paper published in a technical
journal by the U.S. Defense Threat Reduction Agency4. Fionet has
proven to be a reliable rapid diagnostic testing solution during
the outbreak of the COVID-19 pandemic.
Prior to the outbreak of the COVID-19 pandemic,
Fionet was successfully used to test and track over one million
patients in remote settings around the world for infectious
diseases including malaria, HIV and dengue fever.
The Fionet Platform was most recently deployed
for COVID-19 testing at the 46th edition of the Toronto
International Film Festival (TIFF), FIFA qualifying matches in
advance of the World Cup in Qatar 2022, and at Canada’s largest
international airport. Ongoing testing engagements of COVID-19
rapid testing with the largest Canadian lab will continue
throughout the nation.
The Company announces that it has granted an
aggregate of 500,000 options to purchase common shares of the
Company at today’s closing price, and expiring five (5) years from
the date of grant, to certain officers, directors and consultants
of the Company.
RECENT NEWS: Relay announces
agreement with Unisys (NYSE: UIS)5, a global IT solutions company,
to market a combined solution for COVID-19 and biosecurity market
needs: https://bit.ly/3AqDI0h
SUBSCRIBE: For more information
on Relay or to subscribe to the Company’s mail list
visit: https://www.relaymedical.com/news
About Relay Medical Corp.
Relay Medical is a technology innovator
headquartered in Toronto, Canada focused on the development of
novel solutions in the diagnostics, AI data science and IoT
security sectors.
Website: www.relaymedical.com
Contact:Destine LeeMedia &
CommunicationsRelay Medical Corp.Office. 647-872-9982TF.
1-844-247-6633Media Inquiries: media@relaymedical.com Investor
Relations: investor.relations@relaymedical.com
Forward-looking Information Cautionary
StatementExcept for statements of historic fact, this news
release contains certain "forward-looking information" within the
meaning of applicable securities law. Forward-looking information
is frequently characterized by words such as "plan", "expect",
"project", "intend", "believe", "anticipate", "estimate" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements are based on the
opinions and estimates at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors
that could cause actual events or results to differ materially from
those anticipated in the forward-looking statements including, but
not limited to delays or uncertainties with regulatory approvals,
including that of the CSE. There are uncertainties inherent in
forward-looking information, including factors beyond the Company’s
control. There are no assurances that the commercialization plans
for the technology described in this news release will come into
effect on the terms or time frame described herein. The Company
undertakes no obligation to update forward-looking information if
circumstances or management's estimates or opinions should change
except as required by law. The reader is cautioned not to place
undue reliance on forward-looking statements. Additional
information identifying risks and uncertainties that could affect
financial results is contained in the Company’s filings with
Canadian securities regulators, which filings are available at
www.sedar.com.
___________________________________1
https://www.who.int/news-room/fact-sheets/detail/malaria2
https://en.wikipedia.org/wiki/Rwanda3 MALARIA DEATH RATE BY COUNTRY
(worldlifeexpectancy.com)4
https://www.sciencedirect.com/science/article/pii/S22141804183004125 https://www.nyse.com/quote/XNYS:UIS
Unisys (NYSE:UIS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Unisys (NYSE:UIS)
Historical Stock Chart
From Mar 2023 to Mar 2024